The anchor underpinning trust in the U.S. monetary system, that is the confidence in the Federal Reserve’s ability to keep consumer price changes on track, is facing its most severe test in decades, as inflation expectations spiral. read more
Although Coinbase’s imminent death cross seemingly spells trouble, the signal could be a contrarian one for COIN stock. read more
Eli Lilly’s donanemab faces a setback as EMA’s CHMP issues a negative opinion. Analysts expect Lilly to appeal, citing past reversals in similar cases. Latest Ratings for LLY Date Firm Action From To Feb 2022 Morgan Stanley Maintains Overweight Feb 2022 Mizuho Maintains Buy Jan 2022 Morgan Stanley Maintains Overweight View More Analyst Ratings for…
FDA approves Novartis’ Pluvicto for advanced prostate cancer patients who have received ARPI therapy. read more
JP Morgan analyst Jeremy Tonet remains bullish on the “washed out” power sector, citing strong demand growth and favorable trends despite regulatory uncertainty. Latest Ratings for CEG Date Firm Action From To Mar 2022 Mizuho Initiates Coverage On Neutral Feb 2022 UBS Initiates Coverage On Neutral Feb 2022 Barclays Initiates Coverage On Overweight View More…
Topcon launches a management buyout with KKR and JIC Capital, offering 3,300 yen per share. The move supports its long-term vision and strategic transformation. read more
Macro analyst Capital Flows has identified Bitcoin‘s (CRYPTO: BTC) increasing correlation with traditional risk assets, particularly low-quality banks in the Russell index, as key to understanding its price trajectory in the read more
